Biotech entity
All 1 tracked stories fall under one category: clinical-trial. Of the tracked stories, 1 of 1 also mention ACESOT-1051, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Biotech story that mention WEE1 kinase inhibitor program, all published on August 29, 2026.
Last mentioned: Aug 29, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: clinical-trial. Of the tracked stories, 1 of 1 also mention ACESOT-1051, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Biotech story that mention WEE1 kinase inhibitor program, all published on August 29, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 1 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering WEE1 kinase inhibitor program. Shared-story counts are live from our verified record — not editorial picks.
Aprea's expanded patent estate covers its DNA damage response pipeline, including lead WEE1 inhibitor APR-1051 in Phase 1. The IP package protects biomarker-defined cancer programs targeting WEE1 and ATR kinases.
WEE1 kinase inhibitor program is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
